A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma
- PMID: 24457057
- PMCID: PMC3909384
- DOI: 10.1186/1479-5876-12-19
A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma
Abstract
Background: E1694 tested GM2-KLH-QS21 vaccine versus high-dose interferon-α2b (HDI) as adjuvant therapy for operable stage IIB-III melanoma. We tested banked serum specimens from patients in the vaccine arm of E1694 for prognostic biomarkers.
Methods: Aushon Multiplex Platform was used to quantitate baseline serum levels of 115 analytes from 40 patients. Least absolute shrinkage and selection operator proportional hazard regression (Lasso PH) was used to select markers that are most informative for relapse-free survival (RFS) and overall survival (OS). Regular Cox PH models were then fit with the markers selected by the Lasso PH. Survival receiver operating characteristic (ROC) analysis was used to evaluate the ability of the models to predict 1-year RFS and 5-year OS.
Results: Four markers that include Tumor Necrosis Factor alpha Receptor II (TNF-RII), Transforming Growth Factor alpha (TGF-α), Tissue Inhibitor of Metalloproteinases 1 (TIMP-1), and C-reactive protein (CRP) were found to be most informative for the prediction of OS (high levels correlate with worse prognosis). The dichotomized risk score based on the four markers could significantly separate the OS curves (p = 0.0005). When using the four-marker PH model to predict 5-year OS, we achieved an area under the curve (AUC) of 89% (cross validated AUC = 72%). High baseline TNF-RII was also significantly associated with worse RFS. The RFS with high (above median) TNF-RII was significantly lower than low TNF-RII (p = 0.01).
Conclusions: The biomarker signature consisting of TNFR-II, TGF-α, TIMP-1 and CRP is significantly prognostic of survival in patients with high-risk melanoma and warrants further investigation.
Figures


Similar articles
-
Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.PLoS One. 2015 Jul 20;10(7):e0132745. doi: 10.1371/journal.pone.0132745. eCollection 2015. PLoS One. 2015. PMID: 26192408 Free PMC article. Clinical Trial.
-
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.Clin Cancer Res. 2007 Apr 15;13(8):2422-8. doi: 10.1158/1078-0432.CCR-06-1805. Clin Cancer Res. 2007. PMID: 17438101 Clinical Trial.
-
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.J Clin Oncol. 2001 May 1;19(9):2370-80. doi: 10.1200/JCO.2001.19.9.2370. J Clin Oncol. 2001. PMID: 11331315 Clinical Trial.
-
Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa.Melanoma Res. 2014 Apr;24(2):150-7. doi: 10.1097/CMR.0000000000000050. Melanoma Res. 2014. PMID: 24509407 Free PMC article. Clinical Trial.
-
Prognostic role of elevated preoperative systemic inflammatory markers in localized soft tissue sarcoma.Cancer Biomark. 2016;16(3):333-42. doi: 10.3233/CBM-160571. Cancer Biomark. 2016. PMID: 26835589 Review.
Cited by
-
Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.PLoS One. 2015 Jul 20;10(7):e0132745. doi: 10.1371/journal.pone.0132745. eCollection 2015. PLoS One. 2015. PMID: 26192408 Free PMC article. Clinical Trial.
-
Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors.Oncol Lett. 2016 May;11(5):3354-3360. doi: 10.3892/ol.2016.4391. Epub 2016 Mar 29. Oncol Lett. 2016. PMID: 27123116 Free PMC article.
-
Role of autophagy in chronic kidney diseases.Int J Clin Exp Med. 2015 Dec 15;8(12):22022-9. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26885176 Free PMC article. Review.
-
Recruitment and Expansion of Tregs Cells in the Tumor Environment-How to Target Them?Cancers (Basel). 2021 Apr 13;13(8):1850. doi: 10.3390/cancers13081850. Cancers (Basel). 2021. PMID: 33924428 Free PMC article. Review.
-
Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma.Int J Mol Sci. 2017 Jul 14;18(7):1527. doi: 10.3390/ijms18071527. Int J Mol Sci. 2017. PMID: 28708099 Free PMC article. Review.
References
-
- Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006;90:51–81. - PubMed
-
- Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N. et al.Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010;16:2646–2655. doi: 10.1158/1078-0432.CCR-10-0041. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous